WallStreetZenWallStreetZen

NYSEMKT: ARMP
Armata Pharmaceuticals Inc Stock

$3.88+0.35 (+9.92%)
Updated Feb 28, 2024
ARMP Price
$3.88
Fair Value Price
N/A
Market Cap
$140.25M
52 Week Low
$1.07
52 Week High
$5.26
P/E
-2.35x
P/B
-11.32x
P/S
26.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.05M
Earnings
-$59.51M
Gross Margin
100%
Operating Margin
-1,439.68%
Profit Margin
-1,468.7%
Debt to Equity
-10.1
Operating Cash Flow
-$50M
Beta
0.34
Next Earnings
Mar 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ARMP Overview

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company is headquartered in Marina Del Rey, California and currently employs 30 full-time employees. The firm is focused on the discovery, development and commercialization of phage therapeutics. The firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The firm is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARMP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ARMP is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ARMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ARMP due diligence checks available for Premium users.

Be the first to know about important ARMP news, forecast changes, insider trades & much more!

Valuation

ARMP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.35x
Industry
13.96x
Market
35.52x

ARMP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-11.32x
Industry
6.14x

ARMP's financial health

Profit margin

Revenue
$1.2M
Net Income
-$31.2M
Profit Margin
-2,543.8%
ARMP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARMP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$112.8M
Liabilities
$125.1M
Debt to equity
-10.1
ARMP's short-term assets ($36.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARMP's long-term liabilities ($103.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$9.7M
Investing
-$3.5M
Financing
$24.8M
ARMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARMP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARMP$140.25M+9.92%-2.35x-11.32x
ADAG$139.71M-1.52%-3.75x1.69x
VTGN$140.80M-1.51%-1.52x1.14x
MOLN$141.20M-4.87%-2.12x0.65x
CLLS$141.74M-6.25%-1.55x1.86x

Armata Pharmaceuticals Stock FAQ

What is Armata Pharmaceuticals's quote symbol?

(NYSEMKT: ARMP) Armata Pharmaceuticals trades on the NYSEMKT under the ticker symbol ARMP. Armata Pharmaceuticals stock quotes can also be displayed as NYSEMKT: ARMP.

If you're new to stock investing, here's how to buy Armata Pharmaceuticals stock.

What is the 52 week high and low for Armata Pharmaceuticals (NYSEMKT: ARMP)?

(NYSEMKT: ARMP) Armata Pharmaceuticals's 52-week high was $5.26, and its 52-week low was $1.07. It is currently -26.18% from its 52-week high and 262.62% from its 52-week low.

How much is Armata Pharmaceuticals stock worth today?

(NYSEMKT: ARMP) Armata Pharmaceuticals currently has 36,146,574 outstanding shares. With Armata Pharmaceuticals stock trading at $3.88 per share, the total value of Armata Pharmaceuticals stock (market capitalization) is $140.25M.

Armata Pharmaceuticals stock was originally listed at a price of $183,750.00 in Dec 31, 1997. If you had invested in Armata Pharmaceuticals stock at $183,750.00, your return over the last 26 years would have been -100%, for an annualized return of -33.9% (not including any dividends or dividend reinvestments).

How much is Armata Pharmaceuticals's stock price per share?

(NYSEMKT: ARMP) Armata Pharmaceuticals stock price per share is $3.88 today (as of Feb 28, 2024).

What is Armata Pharmaceuticals's Market Cap?

(NYSEMKT: ARMP) Armata Pharmaceuticals's market cap is $140.25M, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Armata Pharmaceuticals's market cap is calculated by multiplying ARMP's current stock price of $3.88 by ARMP's total outstanding shares of 36,146,574.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.